Conjugate Vaccine Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

The Conjugate Vaccine Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Conjugate Vaccine Market:
https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

According to The Business Research Company’s Conjugate Vaccine Global Market Report 2024, The conjugate vaccine market size has grown rapidly in recent years. It will grow from $16.77 billion in 2023 to $19.11 billion in 2024 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to disease burden, government immunization programs, increased awareness, pediatric vaccination emphasis, preventive healthcare trends..

The conjugate vaccine market size is expected to see rapid growth in the next few years. It will grow to $30.65 billion in 2028 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to expanding immunization policies, aging population dynamics, new vaccine indications, global health security concerns, international collaboration, economic development impact. Major trends in the forecast period include collaborations and partnerships for vaccine distribution, tailored approaches for high-risk populations, application in emerging infectious diseases, advancements in vaccine manufacturing technologies, global health initiatives for vaccine equity..

The increase in the use of conjugate vaccines for adults is expected to propel the growth of the conjugate vaccine market. Conjugate vaccines are designed to stimulate a strong immune response against bacterial capsular polysaccharides, enhancing the body’s defense mechanism against bacterial infections. The use of conjugate vaccines in adults helps reduce the risk of severe illness, complications, and transmission of these bacterial diseases by stimulating a robust immune response. For instance, according to the Historical national influenza vaccination coverage 2020-2022, published by the National Centre for Immunization Research and Surveillance, an Australia-based research organization, historical influenza vaccine coverage at the end of 2022 by 15 – < 50 years age group was 29.5%, an increase from 22.8% recorded in 2021. Therefore, the increase in the use of conjugate vaccines for adults is driving the growth of the conjugate vaccine market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=10850&type=smp

The conjugate vaccine market covered in this report is segmented –

1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine
2) By Pathogen: Bacterial, Viral
3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid
4) By Patient: Pediatric, Adults
5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users

Innovation in conjugate vaccines is a key trend gaining popularity in the conjugate vaccine market. Companies operating in the conjugate vaccine market are focused on developing innovative conjugate vaccines to sustain their position in the market. For instance, in June 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology company, launched Prevnar 20, a pneumococcal 20-valent conjugate vaccine, in Canada to prevent pneumonia and invasive pneumococcal infections in adults aged 18 and older. Prevnar 20 includes conjugates for the 13 serotypes already covered by PREVNAR 13 and conjugates for seven additional serotypes associated with invasive pneumococcal disease, high case-fatality rates, antibiotic resistance, and meningitis.

The conjugate vaccine market report table of contents includes:

1. Executive Summary
2. Conjugate VaccineMarket Characteristics
3.Conjugate Vaccine Market Trends And Strategies
4. Conjugate VaccineImpact Of Market analysis
5. Conjugate VaccineMarket Size And Growth
6.Conjugate Vaccine Segmentation
7. Conjugate VaccineRegional And Country Analysis
.
.
.
27. Conjugate VaccineCompetitive Landscape And Company Profiles
28.Conjugate Vaccine Key Mergers And Acquisitions
29. Conjugate VaccineFuture Outlook and Potential Analysis

TOP MAJOR PLAYERS:

• Sanofi S.A.
• Pfizer Inc. Merck & Co. Inc.
• GlaxoSmithKline PLC
• Bharat Biotech International Limited
• Serum Institute of India Private Limited

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model